

SUBSCRIBE TO OUR FREE NEWSLETTER
Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.
5
#000000
#FFFFFF
To donate by check, phone, or other method, see our More Ways to Give page.


Daily news & progressive opinion—funded by the people, not the corporations—delivered straight to your inbox.

"At a time when the United States pays, by far, the highest prices in the world for prescription drugs, the last thing we need is to put a pharmaceutical executive in charge of the Department of Health and Human Services," Sanders said in a statement. (Photo: Gage Skidmore/Flickr/cc)
Following news on Monday that President Donald Trump has picked Alex Azar--former top executive at the pharmaceutical giant Eli Lilly--to run the Department of Health and Human Services, Sen. Bernie Sanders (I-Vt) issued a statement characterizing the choice as evidence that "Trump was never serious about his promise to stop the pharmaceutical industry from 'getting away with murder'" and vowing to oppose his confirmation.
"At a time when the United States pays, by far, the highest prices in the world for prescription drugs, the last thing we need is to put a pharmaceutical executive in charge of the Department of Health and Human Services (HHS)," Sanders said.
As Common Dreams has reported, Sanders and several top congressional Democrats introduced legislation in October with the goal of pressuring Trump to act on his criticism of the drug industry by allowing the government to negotiate lower prices for prescription drugs.
But Sanders concluded on Monday that Trump's selection of an industry insider like Azar to head HHS demonstrates that the president has no intention of turning his expressed support for lower drug prices into policy.
"During Mr. Azar's tenure at Eli Lilly, this multi-billion-dollar corporation dodged taxes while charging Americans outrageously high prices for life-saving prescription drugs," Sanders concluded. "We need an HHS secretary who is willing to take on the greed of the pharmaceutical industry and lower prescription drug prices, not one who has financially benefited from this greed."
Sanders was far from the only lawmaker raising significant concerns about Azar's nomination, given his deep ties to the industry he will be charged with regulating if he makes it through the Senate confirmation process.
"If my priority were bringing down Rx prices, I probably wouldn't tap a pharmaceutical industry exec accused of colluding to drive up the cost of insulin," Sen. Jeff Merkley (D-Oreg.) wrote on Twitter.
This country and this world are at a monumental crossroads. US voters have an opportunity to beat back the forces of fascism and confront the billionaires who are rigging the economy, our media system, and our democracy, making it increasingly impossible for ordinary people to get by. We’re not just talking about the election. We’re talking about what must be done once these fascist elements are vanquished from power. We need a bolder set of solutions than what either major party has so far been willing to offer and a working-class movement ready to fight like hell for it. Trump didn't emerge from nowhere. The conditions that fueled MAGA authoritarianism were created by decades of radical neoliberal economic policies and a corrupt political system dominated by corporate interests. They slashed taxes on the super-rich, promising that the benefits would trickle down. They said giveaways to the corporate titans would make life more affordable for the rest of us. It was all bullshit. And when a bitter, betrayed populace searches for someone to blame, right-wing demagogues have little trouble finding scapegoats. People know when they're being lied to, but you won't hear any of this from the corporate media. Only independent journalism—powered and funded by people who believe in building a better world—can deliver truly trustworthy daily news. If you share our vision, please contribute whatever you can to sustain our work. |
Following news on Monday that President Donald Trump has picked Alex Azar--former top executive at the pharmaceutical giant Eli Lilly--to run the Department of Health and Human Services, Sen. Bernie Sanders (I-Vt) issued a statement characterizing the choice as evidence that "Trump was never serious about his promise to stop the pharmaceutical industry from 'getting away with murder'" and vowing to oppose his confirmation.
"At a time when the United States pays, by far, the highest prices in the world for prescription drugs, the last thing we need is to put a pharmaceutical executive in charge of the Department of Health and Human Services (HHS)," Sanders said.
As Common Dreams has reported, Sanders and several top congressional Democrats introduced legislation in October with the goal of pressuring Trump to act on his criticism of the drug industry by allowing the government to negotiate lower prices for prescription drugs.
But Sanders concluded on Monday that Trump's selection of an industry insider like Azar to head HHS demonstrates that the president has no intention of turning his expressed support for lower drug prices into policy.
"During Mr. Azar's tenure at Eli Lilly, this multi-billion-dollar corporation dodged taxes while charging Americans outrageously high prices for life-saving prescription drugs," Sanders concluded. "We need an HHS secretary who is willing to take on the greed of the pharmaceutical industry and lower prescription drug prices, not one who has financially benefited from this greed."
Sanders was far from the only lawmaker raising significant concerns about Azar's nomination, given his deep ties to the industry he will be charged with regulating if he makes it through the Senate confirmation process.
"If my priority were bringing down Rx prices, I probably wouldn't tap a pharmaceutical industry exec accused of colluding to drive up the cost of insulin," Sen. Jeff Merkley (D-Oreg.) wrote on Twitter.
Following news on Monday that President Donald Trump has picked Alex Azar--former top executive at the pharmaceutical giant Eli Lilly--to run the Department of Health and Human Services, Sen. Bernie Sanders (I-Vt) issued a statement characterizing the choice as evidence that "Trump was never serious about his promise to stop the pharmaceutical industry from 'getting away with murder'" and vowing to oppose his confirmation.
"At a time when the United States pays, by far, the highest prices in the world for prescription drugs, the last thing we need is to put a pharmaceutical executive in charge of the Department of Health and Human Services (HHS)," Sanders said.
As Common Dreams has reported, Sanders and several top congressional Democrats introduced legislation in October with the goal of pressuring Trump to act on his criticism of the drug industry by allowing the government to negotiate lower prices for prescription drugs.
But Sanders concluded on Monday that Trump's selection of an industry insider like Azar to head HHS demonstrates that the president has no intention of turning his expressed support for lower drug prices into policy.
"During Mr. Azar's tenure at Eli Lilly, this multi-billion-dollar corporation dodged taxes while charging Americans outrageously high prices for life-saving prescription drugs," Sanders concluded. "We need an HHS secretary who is willing to take on the greed of the pharmaceutical industry and lower prescription drug prices, not one who has financially benefited from this greed."
Sanders was far from the only lawmaker raising significant concerns about Azar's nomination, given his deep ties to the industry he will be charged with regulating if he makes it through the Senate confirmation process.
"If my priority were bringing down Rx prices, I probably wouldn't tap a pharmaceutical industry exec accused of colluding to drive up the cost of insulin," Sen. Jeff Merkley (D-Oreg.) wrote on Twitter.